HeartSciences Inc. (HSCSW)
| Market Cap | 14.59M +287.8% |
| Revenue (ttm) | 4,519 -76.6% |
| Net Income | -10.26M |
| EPS | -3.19 |
| Shares Out | 4.80M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6 |
| Open | 0.0750 |
| Previous Close | 0.0610 |
| Day's Range | 0.0750 - 0.0750 |
| 52-Week Range | 0.0349 - 0.1800 |
| Beta | 1.81 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Dec 14, 2026 |
About HSCSW
HeartSciences Inc., a medical technology company, focuses on advancing electrocardiography (ECG) through the integration of artificial intelligence. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction, as well as conventional ECG information in the same test; and MyoVista Insights, a cloud-native vendor- and device-agnostic EC... [Read more]
News
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on November 18, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on November 17, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Registration statement: Registration filing
HeartSciences filed a registration statement on November 17, 2026, providing details about a securities offering with the SEC.
Fortitude Reports Financial and Operating Results for the Nine Months Ended September 30, 2026
Company generated $57.9 million in revenue and Adjusted EBITDA of $17.1 million during the nine-month period ended September 30, 2026
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on November 13, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on November 13, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on November 12, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on November 10, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on November 10, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on November 10, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on November 9, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on November 6, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on November 6, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on November 5, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on November 4, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on November 3, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on November 2, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on October 30, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on October 29, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences announces 15-MW facility in Nebraska participates in SPP
Fortitude Mining announced that its 15-megawatt, MW, facility in Aurora, Nebraska, is participating in the Southwest Power Pool, SPP, wholesale electricity markets through Dispatchable Demand Response...
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on October 28, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on October 27, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on October 26, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on October 26, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences sets November 19 vote on Fortitude Mining combination
HeartSciences (HSCS) announced that it has filed its definitive proxy statement with the SEC in connection with its previously announced proposed business combination with Fortitude Mining Holdings, a...